|
Interrogating immune signatures in the thoracic duct of patients with multiple sclerosis |
1F31AI167501-01 |
|
NIAID |
2022 |
|
Role of Natural Killer Cell Diversity in Multiple Sclerosis Risk and Disease Course |
1R01AI169070-01A1 |
|
NIAID |
2022 |
|
Long non-coding RNA signatures to distinguish relapsing-remitting multiple sclerosis from primary progressive and secondary progressive multiple sclerosis |
1R43AI157674-01A1 |
|
NIAID |
2022 |
|
Project 3: Integrative approach tounderstanding the mechanism ofcostimulation
[Parent Title: Costimulatory Mechanisms of Autoimmunity] |
5 P01 AI039671-24 |
SHARPE, ARLENE H |
NIAID |
2021 |
|
Long non-coding RNA signatures to track treatment responses in multiple sclerosis |
5 R44 AI145505-03 |
SPURLOCK, CHARLES FLOYD |
NIAID |
2021 |